News items:
-
Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer
Research collaboration has resulted in new ‘liquid biopsy’ research workflowusing nanopore sequencing to detect molecules that are associated with cancer,circulating in blood. Thursday 16th March Oxford Nanopore Technologies and Dutch start-up Cyclomics today announced the ‘developeraccess’ of a new research workflow that combines the world’s first nanopore sequencing-basedsolution for ultra-sensitive detection of circulating tumour DNA… Read More »Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer
-
Cyclomics announces completion of seed financing round
To accelerate the development of innovate technologies in the field of cancer genetic testing, Cyclomics has completed a financing round driven by a group of private investors. In recent years, the primary focus of Cyclomics has been on the development of its core CyclomicsSeq technology, which has found its way in multiple collaborative research projects… Read More »Cyclomics announces completion of seed financing round
-
Appointment of Rodrigo Meneses as Bioinformatics Scientist at Cyclomics
We are happy to announce the expansion of our bioinformatics team with the addition of Rodrigo Meneses. Rodrigo has a Masters degree in Bioinformatics from Ghent University and a strong biological background due to his degree from the University of Aveiro. His experience within a medical setting is a great addition to the team and… Read More »Appointment of Rodrigo Meneses as Bioinformatics Scientist at Cyclomics
-
Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.
We are happy to announce our newest team member to join Cyclomics. With a background in Biology, Rita Ferreira holds a PhD degree in Medical Microbiology (2022) from the University of Groningen. Rita’s expertise in cell and molecular biology will contribute to the design and implementation of novel molecular assays and the overall development of… Read More »Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.
-
Cyclomics finalizes Oncode clinical proof-of-concept project
Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute… Read More »Cyclomics finalizes Oncode clinical proof-of-concept project
-
Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium
Cyclomics’ CSO Wigard Kloosterman presented the CyclomicsSeq technology at the online Cancer Research Symposium organised by Oxford Nanopore Technologies. The recording of the presentation is now available online. The presentation covers details of the CyclomicsSeq technology, which enables consensus sequencing of DNA fragments using the Oxford Nanopore sequencing instruments. Cyclomics aims at delivering flexible, accurate… Read More »Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium
-
Cyclomics announces publication on CyclomicsSeq technology
We are excited to announce the publication about Cyclomics’ core CyclomicsSeq technology in Genomic Medicine. CyclomicsSeq technology involves a novel consensus sequencing approach fully optimised for circulating tumor DNA. The small size and low abundance of circulating tumor DNA in the blood of cancer patients makes accurate detection of cancer mutations difficult. Cyclomics has established a… Read More »Cyclomics announces publication on CyclomicsSeq technology
-
Appointment of Dàmi Rebergen as bioinformatician at Cyclomics
We are happy to announce the appointment of Dàmi Rebergen to strengthen the bioinformatics capabilities of Cyclomics. Dàmi Rebergen has a bioinformatics degree from Wageningen University (2019) and has recent experience working at startup and biotech companies in The Netherlands and the UK. At Cyclomics, Dàmi will perform a key role in the establishment of a… Read More »Appointment of Dàmi Rebergen as bioinformatician at Cyclomics
-
CyclomicsSeq manuscript available as preprint
We are happy to announce the publication of our preprint manuscript about CyclomicsSeq on biorxiv.org. The manuscript describes our technology for capturing, amplifying, and high-accuracy sequencing of short circulating tumor DNA molecules from patients with cancer. We have developed CyclomicsSeq to be compatible with any long-read DNA sequencer and have extensively tested the technology with… Read More »CyclomicsSeq manuscript available as preprint
-
Cyclomics and University Medical Center Utrecht sign collaboration agreement
Following the licensing of liquid biopsy technology owned by the University Medical Center Utrecht (UMC Utrecht), Cyclomics and the UMC Utrecht have entered into a long-standing collaboration to strengthen the synergy between both parties further, and drive technological innovation and clinical evaluation of the CyclomicsSeq platform technology. The agreement is an essential milestone for Cyclomics… Read More »Cyclomics and University Medical Center Utrecht sign collaboration agreement
-
Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer
Research collaboration has resulted in new ‘liquid biopsy’ research workflowusing nanopore sequencing to detect molecules that are associated with cancer,circulating in blood. Thursday 16th March Oxford Nanopore Technologies and Dutch start-up Cyclomics today announced the ‘developeraccess’ of a new research workflow that combines the world’s first nanopore sequencing-basedsolution for ultra-sensitive detection of circulating tumour DNA… Read More »Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer